According to product SmPCs, nausea affects approximately 15-30% of patients on standard doses, though rates vary by specific product and dose, with higher frequencies during dose escalation
Additionally, it has been used to enhance liver function, reduce inflammation, and fortify the immune system
The documented schedule holds each step for about four weeks specifically because faster escalation sharply increases nausea and vomiting and drives dropout
ORAL WEGOVY PA QUESTIONS Frequently Asked Questions Yes
Figure 4: Time to First Occurrence of Hospitalization for Heart Failure or CV Death in the DECLARE Trial Figure 5: Time to First Occurrence of Hospitalization for Heart Failure in the DECLARE Trial 14.4 Chronic Kidney Disease in Adults The Trial to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease (DAPA-CKD, NCT03036150) was an international, multicenter, randomized, double-blind, placebo-controlled trial in adult patients with chronic kidney disease (CKD) (eGFR between 25 and 75 mL/min/1.73 m2) and albuminuria [urine albumin creatinine ratio (UACR) between 200 and 5000 mg/g] who were receiving standard of care background therapy, including a maximally tolerated, labeled daily dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB)
